 HAIFA, Israel, Feb. 02, 2021 GLOBE NEWSWIRE -- Pluristem Therapeutics Inc. Nasdaq:PSTI TASE:PSTI, a leading regenerative medicine company developing a platform of novel biological therapeutic products Pluristem or the Company, today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of 6.30 per share in a registered direct offering, for gross proceeds of 30 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about February 4, 2021, subject to the satisfaction of customary closing conditions. 